From Bloomberg:
Johnson & Johnson won approval in Sweden and Finland for the first prescription pill to treat premature ejaculation, three years after U.S. regulators rejected the drug, the company said.
The drugmaker expects to win clearance for dapoxetine, to be sold as Priligy, in five more European nations and has applied for approval in Canada, Australia, Mexico, Turkey and six other countries, said Greg Panico, a spokesman for New Brunswick, New Jersey-based J&J, today in a telephone interview. The pill, taken a few hours before intercourse, should be in European drugstores by April, he said.
“There’s a globally significant market” for premature ejaculation treatments, Panico said. He declined to estimate sales.
Dapoxetine may generate $575 million a year by 2011 for the company, said Michael Weinstein, a JPMorgan Chase & Co. analyst in New York, in an Oct. 29 note to clients. It’s one of several drugs J&J is developing to replace revenue it expects to lose to generic competition to top-selling medications such as the antipsychotic Risperdal, he said. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment